News Focus
News Focus
icon url

shadolane

12/14/22 7:27 PM

#395691 RE: Tatsumaki #395681

Everything has gone up in smoke.
icon url

TastyTheElf

12/15/22 7:26 AM

#395755 RE: Tatsumaki #395681

If that is accurate -- and it may well be -- then it's over.

The present value of free cash flow off this indication is $0. Projected revenue - normal expenses - executive pigs at the trough = $0.

I will say this though. If the thesis on the MOA of EPA is really true, then CVD efficacy can't be all there is. It simply can't be. The impacts of systemic inflammation are legion.
icon url

Nukemtiltheyglow

12/15/22 9:26 AM

#395763 RE: Tatsumaki #395681

Don’t tell that to Novartis, after their purchase of Medco for $10B. Heck, who’d want to pay $7k a year for two (2) shots of Inclisiran?
icon url

Meowza

12/15/22 1:18 PM

#395804 RE: Tatsumaki #395681

Nobody's gonna drop huge cash on a Alz clinical with 0 market exclusivity


Nobody's gonna drop huge cash on a Alz clinical with 0 market exclusivity


Nobody's gonna drop huge cash on a Alz clinical with 0 market exclusivity


Nobody's gonna drop huge cash on a Alz clinical with 0 market exclusivity


Nobody's gonna drop huge cash on a Alz clinical with 0 market exclusivity


Nobody's gonna drop huge cash on a Alz clinical with 0 market exclusivity